3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1161-1170

  Hamasaki, Yoshifumi ^a   Doi, Kent ^a   Okamoto, Koji ^a   Ijichi, Hideaki ^a   Seki, George ^a   Maeda Mamiya, Rui ^a   Fujita, Toshiro ^a   Noiri, Eisei ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

BMP 7; HOXA13; statin; TGF 1; USAG 1

Indexed keywords

ADENINE; ALPHA SMOOTH MUSCLE ACTIN; HOMEOBOX PROTEIN HOXA13; HOMEODOMAIN PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; OSTEOGENIC PROTEIN 1; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DRUG MECHANISM; EPITHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CELL CULTURE; KIDNEY DISTAL TUBULE; KIDNEY DYSFUNCTION; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; UTERINE SENSITIZATION ASSOCIATED GENE 1;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; CELL LINE; DOGS; FEMALE; FIBROSIS; HOMEODOMAIN PROTEINS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 84864442350     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.71     Document Type: Article

References (55)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
2. Trivedi H. Cost implications of caring for chronic kidney disease: are interventions cost-effective? Adv Chronic Kidney Dis 2010;17: 265-270.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
4. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-296.
5. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;2: 363-366.
6. Mackensen-Haen S, Bader R, Grund KE, et al. Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 1981;15:167-171.
7. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1-17.
8. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
9. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
10. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
11. Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543; 531p following 143.
12. Kassimatis TI, Konstantinopoulos PA. The role of statins in chronic kidney disease (CKD): friend or foe? Pharmacol Ther 2009;122:312-323.
13. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008;74:571-576.
14. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-288.
15. Vieira Jr JM, Mantovani E, Rodrigues LT, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582-1591.
16. Patel S, Mason RM, Suzuki J, et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol 2006;26:381-387.
17. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, et al. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008;25:2447-2461.
18. Yanagita M, Oka M, Watabe T, et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun 2004;316:490-500.
19. Yanagita M, Okuda T, Endo S, et al. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 2006;116:70-79.
20. Tanaka T, Doi K, Maeda-Mamiya R, et al. Urinary L-type fatty acidbinding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009;174:1203-1211.
21. Chade AR, Zhu XY, Grande JP, et al. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens 2008;26:1651-1660.
22. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol 2008;179:1631-1636.
23. Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714-723.
24. Yuen PS, Dunn SR, Miyaji T, et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004;286:F1116-F1119.
25. Doi K, Okamoto K, Negishi K, et al. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptordeficient mice. Am J Pathol 2006;168:1413-1424.
26. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 1999;276(Part 2):F39-F45.
27. Knosp WM, Saneyoshi C, Shou S, et al. Elucidation, quantitative refinement, and in vivo utilization of the HOXA13 DNA binding site. J Biol Chem 2007;282:6843-6853.
28. Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007;18: 1497-1507.
29. Zhang A, Dong Z, Yang T. Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. Am J Physiol Renal Physiol 2006;291:F1332-F1342.
30. Hartung R, Parapuram SK, Ganti R, et al. Vitreous induces heme oxygenase-1 expression mediated by transforming growth factor-beta and reactive oxygen species generation in human retinal pigment epithelial cells. Mol Vis 2007;13:66-78.
31. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 1995;26:678-690.
32. Reichert M, Muller T, Hunziker W. The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signaling. J Biol Chem 2000;275:9492-9500.
33. Bagnoli F, Buti L, Tompkins L, et al. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci USA 2005;102:16-16.
34. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
35. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-734.
36. Koren MJ, Davidson MH, Wilson DJ, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53:741-750.
37. Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-1613.
38. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-1139.
39. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-819.
40. Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenineinduced chronic renal failure in rats. Nephron 1986;44:230-234.
41. Cochrane AL, Kett MM, Samuel CS, et al. Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol 2005;16:3623-3630.
42. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001;159:1465-1475.
43. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-968.
44. Xu Y, Wan J, Jiang D, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition in human renal proximal tubular epithelial cells. J Nephrol 2009;22:403-410.
45. Gould SE, Day M, Jones SS, et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002;61:51-60.
46. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003;285: F1060-F1067.
47. Morrissey J, Hruska K, Guo G, et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002;13(Suppl 1):S14-S21.
48. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006;21: 568-573.
49. Tanaka M, Asada M, Higashi AY, et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 2010;120: 768-777.
50. Neilson EG. Mechanisms of disease: fibroblasts-A new look at an old problem. Nat Clin Pract Nephrol 2006;2:101-108.
51. Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 2005;280: 8094-8100.
52. Scott V, Morgan EA, Stadler HS. Genitourinary functions of Hoxa13 and Hoxd13. J Biochem 2005;137:671-676.
53. Mortlock DP, Innis JW. Mutation of HOXA13 in hand-foot-genital syndrome. Nat Genet 1997;15:179-180.
54. Fromental-Ramain C, Warot X, Messadecq N, et al. Hoxa-13 and Hoxd-13 play a crucial role in the patterning of the limb autopod. Development 1996;122:2997-3011.
55. Williams TM, Williams ME, Heaton JH, et al. Group 13 HOX proteins interact with the MH2 domain of R-Smads and modulate Smad transcriptional activation functions independent of HOX DNA-binding capability. Nucleic Acids Res 2005;33:4475-4484.